Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355117 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL29398212 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30896049 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486287 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1486214 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL118209 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL119497 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL30896048 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL6038102 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 | |
| SCHEMBL1564185 | 1.00 | CASP3 (0.52) | CASP3MDM4TP53KMT2APIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417402-A | Pseudo dandelion sterol derivative and preparation method and application thereof | 天津科技大学 | 2024-01-19 | — | — | CN | claimed |
| EP-4720097-A1 | PEPTIDES WITH LIPOLYTIC, ANTI-LIPOGENIC, ANTIFIBROTIC AND ANTI-INFLAMMATORY ACTIVITY | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2026-04-08 | — | — | EP | disclosed |
| EP-4685154-A1 | POLYPEPTIDE DERIVED FROM TRIDEGIN | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2026-01-28 | — | — | EP | disclosed |
| EP-4673554-A1 | ASPARAGINYL PEPTIDE LIGASE-MEDIATED RADIOLABELLING OF SINGLE-DOMAIN ANTIBODIES | Nanyang Technological University (SG) | 2026-01-07 | — | — | EP | disclosed |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4482578-B1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CORTERIA PHARMACEUTICALS (FR) | 2025-12-24 | — | — | EP | disclosed |
| US-12458685-B2 | Manufacture, formulation and dosing of apraglutide | VECTIVBIO AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| US-20250186557-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2025-06-12 | — | — | US | disclosed |
| CN-115389693-A | Detection method for simultaneously determining various side chain protection amino acid isomers by HPLC | 河北科技大学 | 2022-11-25 | — | — | CN | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-114989298-A | D-peptide compounds against VEGF | 反射制药有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114874293-A | Cyclic polypeptide compounds and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2022-08-09 | — | — | CN | disclosed |
| WO-2022162332-A1 | ANTIBIOTIC NATURAL PRODUCT ANALOGUES | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2022-08-04 | — | — | WO | disclosed |
| CN-112500457-B | Dual-targeting FOXM1/CDK1 anti-tumor polypeptide | 长沙新生康源生物医药有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114174334-A | D-peptide compounds against VEGF | 反射制药有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-114144433-A | Multivalent D-peptide compounds for proteins of interest | 反射制药有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-20220062384-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | VECTIVBIO AG (CH) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062384-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | CASP3 329/4885MDM4 4715/4885TP53 4243/4885 |
| US-20250186557-A1 | MANUFACTURE, FORMULATION AND DOSING OF APRAGLUTIDE | GLP1R, IAPP, GIPR | CASP3 329/4885MDM4 4715/4885TP53 4243/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | CASP3 2833/4885MDM4 455/4885TP53 8/4885 |
| US-12458685-B2 | Manufacture, formulation and dosing of apraglutide | GLP1R, IAPP, GIPR | CASP3 329/4885MDM4 4715/4885TP53 4243/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | CASP3 2833/4885MDM4 455/4885TP53 8/4885 |
| US-20260001928-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | GIPR, NPY2R, NPY1R | CASP3 4474/4885MDM4 4186/4885TP53 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.